Clinical trials
Fibrosis clinical trials
Below are recruiting fibrosis clinical trials, each written for real people, not researchers. We’re tracking 440 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07417553RecruitingPhase 2
Hydronidone capsules for hepatitis B-related liver scarring
This study tests a new capsule called hydronidone for people with liver scarring caused by chronic hepatitis B. You must already be on stable hepatitis B treatment and have moderate to advanced scarring.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07343778RecruitingPhase 3
Safety of Hydronidone Capsules for Liver Scarring and Cirrhosis
This study tests a new medication called Hydronidone for people with liver scarring (fibrosis) or cirrhosis. It aims to see if the drug is safe and may help slow or improve the condition.
ZhengzhouAges 18 years+ - NCT07251725Recruiting
Genetic study of family-linked lung scarring
This study looks for genetic causes of pulmonary fibrosis that runs in families. You and your affected family member(s) would provide blood samples and health info to help researchers understand why lung scarring happens.
Pavia, LombardyAges 18 years+ - NCT07364448RecruitingPhase 2
Testing Hydronidone for liver fibrosis safety
This trial tests an experimental pill called Hydronidone for people with liver fibrosis (scarring) caused by chronic hepatitis B or fatty liver disease. It aims to see if the drug is safe and may help slow or reverse liver damage.
Jilin City, ChangchunAges 18 years+ - NCT06559150RecruitingPhase 2
Study of ensifentrine for non-cystic fibrosis bronchiectasis
This trial tests an inhaled drug called ensifentrine in people with bronchiectasis (damaged, widened airways in the lungs). The goal is to see if it can reduce flare-ups and improve symptoms.
Birmingham, AlabamaAges 18–80 - NCT06561529Recruiting
Stomach bypass stent for liver scarring in obese patients
This study tests a stomach bypass stent to treat liver scarring caused by fatty liver disease in people with obesity. If you have obesity and a confirmed liver condition called NASH with moderate scarring, this stent might help you achieve weight loss and improve your liver health.
Riga, RigaAges 18–65 - NCT06994221Recruiting
Heart function study after heart attack with aneurysm
This trial looks at how heart scarring after a major heart attack affects the heart's shape and function. It might help people who developed a bulge (aneurysm) in the heart wall after their attack.
ShanghaiAges 18–75 - NCT06919042Recruiting
Shockwave therapy for breast reconstruction scar tissue
This trial tests if a special shockwave treatment can soften firm scar tissue that sometimes forms after breast reconstruction surgery. If you've had plastic surgery and have firm, tight areas under your skin, this study might be able to help.
Chicago, IllinoisAges 18 years+ - NCT06617013Recruiting
GERD in children with cystic fibrosis
This study looks at GERD (reflux) in children with cystic fibrosis. It aims to understand how common it is and how it affects them, which could lead to better care.
Durham, North CarolinaAges 2–18 - NCT06601829Recruiting
Liver and kidney disease study in children
This study looks at children with congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. It aims to learn more about these conditions and how they affect children.
SohagAges Any age - NCT06546943Recruiting
Glucose monitoring in youth with cystic fibrosis
This study uses a continuous glucose monitor (a small sensor on the arm) to track blood sugar levels in young people with cystic fibrosis during a lung infection flare-up (called a pulmonary exacerbation). It aims to see if glucose changes can help guide treatment.
Aurora, ColoradoAges 6–25 - NCT07102043Enrolling by invitation
Glucose study in cystic fibrosis related diabetes
This study looks at how the body handles sugar in people with cystic fibrosis related diabetes. Researchers want to learn more about glucose metabolism to improve care for people with CFRD.
Birmingham, AlabamaAges 21–75 - NCT07616375RecruitingPhase 3
Safety Study of HSK31858 for Bronchiectasis
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
Yixingcun, JiangxiAges 18 years+ - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT07036523RecruitingPhase 2
Study of BI 765423 for people with Idiopathic Pulmonary Fibrosis (IPF)
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
Birmingham, AlabamaAges 40 years+ - NCT07729787Recruiting
Autogenic drainage vs. chest percussion for kids with CF
This trial compares two breathing techniques to help clear mucus from the lungs of children with cystic fibrosis. It aims to see if one method (autogenic drainage) works better than another (mechanical percussion with a vest).
Multan Khurd, Punjab ProvinceAges 6–12 - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT07723872Recruiting
Finger vs. earlobe oxygen test during a 6-minute walk
This study compares oxygen levels measured at the finger versus the earlobe during a 6-minute walk test for people with interstitial lung disease. It helps find the most accurate way to monitor your oxygen during exercise.
Granollers, SpainAges 18 years+ - NCT06968845RecruitingPhase 2
Study of LTI-03 for Idiopathic Pulmonary Fibrosis
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
Birmingham, AlabamaAges 40 years+ - NCT07284602RecruitingPhase 3
Comparing a new drug to pirfenidone for lung scarring
This trial tests a new medicine, LYT-100 (deupirfenidone), against the standard drug pirfenidone for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the new drug works better or has fewer side effects.
Palm Spring, CaliforniaAges 40 years+ - NCT07516951RecruitingPhase 2
Study of zampilimab for idiopathic pulmonary fibrosis
This trial tests an investigational drug called zampilimab for people with idiopathic pulmonary fibrosis (IPF). It aims to find a safe and effective dose that may slow lung function decline.
SkopjeAges 40 years+ - NCT07707245Recruiting
Finding biomarkers in lung disease and lung cancer
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
Milan, MilanAges 18 years+ - NCT07275905RecruitingPhase 1
Phage therapy for adults with cystic fibrosis and achromobacter infection
This trial tests a cocktail of viruses (bacteriophages) that target achromobacter bacteria in the lungs of adults with cystic fibrosis. It aims to see if the phages are safe and can reduce the infection.
San Diego, CaliforniaAges 18 years+ - NCT02965326Recruiting
Testing blood and swab markers to track new cystic fibrosis treatments
This study looks for simple signals (markers) that may show whether cystic fibrosis treatments are working. It includes people who take CF “modulator” medicines like ivacaftor, people who don’t, and people whose cystic fibrosis was ruled out after testing.
ParisAges Any age
Hear when a new Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fibrosis?
- Yes. Clin2 currently lists 440 recruiting fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.